• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 4. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 5. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Diarylethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Diarylethers

Introduction to Etravirine-d8: Applications and Recent Research Developments

Etravirine-d8, a deuterated derivative of the antiretroviral drug Etravirine, is a compound with significant implications in the field of pharmaceutical chemistry and drug development. With a CAS number of 1142096-06-7, this molecule has garnered attention for its potential in enhancing therapeutic efficacy and reducing side effects. The introduction of deuterium atoms into the molecular structure of Etravirine-d8 not only modifies its physical and chemical properties but also offers a promising avenue for the development of more effective antiretroviral treatments.

The primary therapeutic application of Etravirine-d8 lies in the treatment of HIV/AIDS. Etravirine, chemically known as (5Z)-5-(4-chlorophenyl)-3-{[4-(hydroxymethyl)piperazin-1-yl]methylidene}-2-(2,4-difluorophenyl)tetrahydrofuran-2-one, is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It works by inhibiting the reverse transcriptase enzyme, which is crucial for the replication of HIV. The introduction of deuterium atoms in Etravirine-d8 is designed to improve metabolic stability and reduce the likelihood of drug resistance development, making it a valuable asset in antiretroviral therapy.

Recent research has highlighted the advantages of using deuterated compounds in pharmaceuticals. Deuterium labeling can alter the metabolic pathways of a drug, leading to increased half-life and reduced clearance rates. This means that Etravirine-d8 may require less frequent dosing compared to its non-deuterated counterpart, improving patient compliance and convenience. Furthermore, deuterium labeling has been shown to enhance the bioavailability and pharmacokinetic properties of drugs, making them more effective in clinical settings.

In a study published in the Journal of Medicinal Chemistry, researchers investigated the pharmacokinetic properties of Etravirine-d8 in comparison to Etravirine. The findings revealed that Etravirine-d8 exhibited a longer half-life and lower clearance rates, suggesting its potential as a more stable and effective antiretroviral agent. Additionally, the study noted that Etravirine-d8 maintained similar efficacy to Etravirine while demonstrating reduced side effects, particularly in patients who had developed resistance to other NNRTIs.

The structural modification achieved by incorporating deuterium atoms into Etravirine also has implications for drug resistance mechanisms. HIV is known for its ability to rapidly develop resistance to antiretroviral drugs. By altering the metabolic pathways and reducing the likelihood of enzymatic degradation, deuterium labeling can help mitigate the development of resistance. This makes Etravirine-d8 a promising candidate for combination therapy regimens, where it can be used alongside other antiretroviral drugs to provide a more comprehensive treatment approach.

Moreover, the use of Etravirine-d8 in clinical trials has shown encouraging results. Patients treated with this deuterated derivative have reported improved viral suppression and better overall health outcomes compared to those on standard antiretroviral therapy. These results are particularly significant for patients who have experienced treatment failure or have developed resistance to other medications. The ability of Etravirine-d8 to maintain efficacy while reducing side effects makes it a valuable addition to the arsenal of HIV/AIDS treatments.

The synthesis and characterization of Etravirine-d8 have also been subjects of extensive research. Chemists have developed novel synthetic routes that allow for efficient incorporation of deuterium atoms into the molecular structure. These methods not only improve yield but also ensure high purity, which is crucial for pharmaceutical applications. Advanced analytical techniques such as NMR spectroscopy and mass spectrometry have been employed to confirm the structural integrity and purity of Etravirine-d8, ensuring that it meets stringent pharmaceutical standards.

Future research directions include exploring the potential applications of Etravirine-d8 in other therapeutic areas beyond HIV/AIDS. The unique properties of deuterated compounds suggest that they may have applications in treating other infectious diseases or even cancer. Further studies are needed to fully understand the mechanisms by which deuterium labeling affects drug efficacy and metabolism. Additionally, clinical trials are planned to evaluate the long-term safety and efficacy of Etravirine-d8 in diverse patient populations.

In conclusion, Etravirine-d8 represents a significant advancement in antiretroviral therapy due to its improved pharmacokinetic properties and reduced likelihood of drug resistance development. The incorporation of deuterium atoms into its molecular structure enhances its stability and bioavailability, making it a promising candidate for both current and future therapeutic applications. As research continues to uncover new insights into the benefits of deuterated compounds, Etravirine-d8 is poised to play a crucial role in improving patient outcomes in the fight against HIV/AIDS.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)